WO2001024871A2 - Modulation of intracellular calcium concentration using non-excitatory electrical signals applied to the tissue - Google Patents
Modulation of intracellular calcium concentration using non-excitatory electrical signals applied to the tissue Download PDFInfo
- Publication number
- WO2001024871A2 WO2001024871A2 PCT/IB2000/001523 IB0001523W WO0124871A2 WO 2001024871 A2 WO2001024871 A2 WO 2001024871A2 IB 0001523 W IB0001523 W IB 0001523W WO 0124871 A2 WO0124871 A2 WO 0124871A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- stimulation
- pulse
- generating
- pulses
- heart
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/362—Heart stimulators
- A61N1/365—Heart stimulators controlled by a physiological parameter, e.g. heart potential
- A61N1/36514—Heart stimulators controlled by a physiological parameter, e.g. heart potential controlled by a physiological quantity other than heart potential, e.g. blood pressure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/362—Heart stimulators
- A61N1/3627—Heart stimulators for treating a mechanical deficiency of the heart, e.g. congestive heart failure or cardiomyopathy
Definitions
- This invention relates generally to invasive devices and methods for treatment of the heart, including devices and methods for stimulation of the heart muscle. More particularly, this invention relates to control of cellular tissue, specifically the modulation of intracellular calcium concentration in cardiac muscle cells.
- Cardiac insufficiency characterized inter alia by a reduction in cardiac output
- Cardiac output i.e., the output of the heart per unit time
- stroke volume can be influenced, for example, by changing the strength of cardiac contraction, by changing the length of the cardiac muscle fibers, and by changing contractility of cardiac muscle independent of fiber length.
- the heart rate and rhythm influence the cardiac output both directly and indirectly, since changes in the rate and rhythm also affect myocardial contractility.
- the human body normally regulates the cardiac output in response to body needs by changing the heart rate, as during physical exercise, and/or by adapting the stroke volume. Under pathological conditions, however, some of the normal regulatory mechanisms may be damaged. For example, heart tissue damaged due to myocardial infarct typically cannot sustain normal pumping function, leading to a reduction in stroke volume, and hence of cardiac output. The body may react to such a reduction by increasing the heart rate, thus imposing long term strain on the heart muscles, leading in more severe cases to heart failure. There is thus a need for devices and treatments that can regulate the cardiac output, so as to compensate for the deficiencies in the normal regulation mechanisms.
- a special kind of control can be achieved using implantable electronic devices, which provide excitatory electrical stimulation to the heart to control directly the heart rate and/or rhythm.
- a pacemaker an electronic device which is typically implanted in the heart to support the heart's electrical excitation system or to bypass a blocked portion of the conduction system.
- a defibrillator Another type of cardiac electronic device is a defibrillator, which senses fibrillation in the heart and applies a high voltage impulse to "reset" the heart.
- electronic pacemakers can control the heart rate, however, they are limited in their capacity to enhance cardiac output, and they are known to reduce stroke volume in at least some instances.
- Defibrillators are useful in treating arrhythmia when it occurs (although they are painful to the patient and traumatic to the heart), but they provide no long-term amelioration of cardiac insufficiency. Thus, none of the treatments known in the art allow effective, long-term regulation of cardiac output.
- PCT patent application PCT/IL97/00012 published as WO 97/25098, to Ben-Haim et al., which is incorporated herein by reference, describes methods for modifying the force of contraction of at least a portion a heart chamber by applying a non-excitatory electric field to the heart at a delay after electrical activation of the portion.
- the non-excitatory field is such as does not induce new activation potentials in cardiac muscle cells, but rather modifies the cells' response to the activation.
- a controller comprises a non- excitatory stimulation probe, including one or more non- excitatory stimulation electrodes, at least one sensor, preferably a sensing electrode; and electronic control circuitry, coupled to the stimulation probe and sensor.
- the stimulation electrodes and, preferably, the sensor are implemented in the heart. Alternatively, a sensing electrode may be placed on a body surface.
- the circuitry receives signals from the sensor, indicative of the heart's activity, and responsive thereto, drives the stimulation electrodes to provide non-excitatory electrical stimulation to the heart.
- non-excitatory electrical stimulation in the context of the present patent application and in the claims, refers to electrical pulses that do not induce new activation potentials to propagate in cardiac muscle cells. Rather, such pulses generally affect the response of the heart muscle to the action potentials, possibly by modulating cell contractility within selected segments of the cardiac muscle.
- the effect of the device on intracellular calcium concentration is preferably regulated by changing the timing of the non-excitatory stimulation pulse relative to the heart's activity, preferably relative to the heart's local electrical activity or ECG signals received by the sensing electrode, and/or by changing other pulse characteristics, such as voltage, current, duration, polarity, waveform and frequency of the waveform.
- the device senses the heart's sinus rhythm and applies and synchronizes the stimulation pulse relative thereto, preferably with a delay before the onset of the stimulation pulse.
- the circuitry may analyze the signals, for example, to determine the QT interval, so as to adjust the stimulation pulses responsive thereto.
- the device when the heart's rhythm is irregular, due to ventricular premature beats (VPB's) or other cardiac arrhythmias, the device preferably identifies and analyzes the irregularity, using signal processing methods known in the art, and adjusts or withholds the stimulation pulse accordingly.
- VPB's ventricular premature beats
- the device preferably identifies and analyzes the irregularity, using signal processing methods known in the art, and adjusts or withholds the stimulation pulse accordingly.
- control circuitry is contained within a console external to the body, and the electrodes are fed percutaneously into the subject's vascular system, for example, through the femoral artery, and are implanted in the heart.
- the electrodes are fed percutaneously into the subject's vascular system, for example, through the femoral artery, and are implanted in the heart.
- Such embodiments are useful particularly in short-term therapy to regulate and stabilize the subject's hemodynamics following an insult or trauma, for example, open heart surgery or MI.
- the electronic control circuitry is contained within a miniaturized, implantable case, similar to pacemaker cases known in the art.
- the non-excitatory stimulation electrodes known in the art such as pacing or electrophysiology electrodes.
- the stimulation electrodes comprise large-area carbon electrodes or any other metal electrodes such as titanium nitrate, iridium oxide, most preferably vitreous carbon, or alternatively, pyro-carbon. Both types of carbon materials are known for their compatibility with heart tissue, in-vivo durability and excellent electrical properties, including high electrical conductivity. Thus, they allow a relatively high electrical current to be delivered to a relatively large segment of the heart tissue, without inducing electrical excitation.
- the non-excitatory stimulation electrodes are inserted into one of the blood vessels of the heart, preferably into the coronary sinus, or alternatively, into a coronary artery.
- different stimulation pulses are applied to respective ones or groups of the plurality of stimulation electrodes.
- the different stimulation pulses are applied to the respective electrodes with a predetermined delay between the different pulses. The delay may be varied so as to achieve a desired hemodynamic effect, for example, to maximize the increase in stroke volume.
- the positions of the plurality of stimulation electrodes and/or characteristics of the stimulation pulses applied thereto are optimized responsive to clinical characteristics of the heart.
- a map of the heart is produced, for example, an electrophysiological map, as described in U.S. Patent 5,568,809, or a phase-dependent geometrical map, as described in PCT Patent Application PCT/IL97/00011, both of which are incorporated herein by reference.
- the map includes information regarding the viability of the heart tissue, for example, based on local contractility or electrical activity.
- the non- excitatory stimulation electrodes are then positioned responsive to the map.
- applying the IDS signal includes conveying electrical energy to cells of the heart, such that action potentials are generally not generated in the cells responsive to the application of the non-excitatory signal.
- the IDS signal is applied to improve hemodynamic performance of the heart.
- the IDS signal is applied in order to increase contractility of the heart or, alternatively or additionally, to increase systolic pressure generated by the heart.
- applying the IDS signal includes sensing physiological variables and applying the signal responsive thereto.
- sensing the variable includes detecting an electrical depolarization wave in the tissue.
- sensing the variable includes sensing a hemodynamic parameter.
- applying the pacing pulses include controlling application of the pacing pulses responsive to the variable, wherein controlling the application of the pacing pulses includes making a transition from a first stimulation mode to a second stimulation mode responsive to the variable.
- apparatus for stimulating cardiac tissue including: a plurality of electrodes, which are placed at multiple sites in at least two different chambers of the heart; and an electrical control unit, which applies pacing pulses to two or more of the electrodes at respective pacing sites in the at least two different chambers, and which applies an IDS signal to at least one of the electrodes in a vicinity of one or more of the pacing sites following application of the pacing pulse at the site.
- the at least one of the electrodes to which the IDS signal is applied includes one of the electrodes to which the pacing pulses are applied.
- At least one of the pacing sites is in the left ventricle, and the IDS signal is applied to an electrode in the left ventricle.
- the control unit applies the IDS signal between during a time period which begins between about 0 and 100 ms after the onset of a pacing pulse applied by the control unit, wherein the time period is set so as to substantially eliminate the possibility that a propagating action potential will be generated responsive to application of the IDS signal.
- the time period begins between about 10 and 50 ms after the onset of the pacing pulse.
- the IDS signal is applied in order to increase contractility of the heart or, alternatively or additionally, in order to increase systolic pressure generated by the heart.
- the apparatus includes a sensor, which senses a physiological variable, wherein the control unit receives an input from the sensor and applies the IDS signal responsive thereto.
- the sensor detects an electrical depolarization wave in the tissue.
- the control unit controls application of the pacing pulses responsive to the variable. Further preferably the control unit makes a transition from a first stimulation mode to a second stimulation mode responsive to the variable.
- Fig. 1A is a graph of shortening vs. time, before, during, and after an IDS signal
- Fig. IB is a graph of calcium concentration vs. time
- Fig. 2 A is a graph of calcium concentration vs. time
- Fig. 2B is a graph of shortening vs. time
- Fig. 3 depicts two graphs vs. time, graph (a) representing concentration form vs. time, and graph (b) represents action potential vs. time; and
- Fig. 4 depicts two graphs of concentration force vs. time, (a) being a control and (b) representing the use of a drug.
- This invention is designed to modulate intracellular calcium concentration in a biological tissue using a non-excitatory electrical signal (IDS).
- IDS non-excitatory electrical signal
- the invention relates to the modulation of the intracellular calcium in cardiac muscle cells and thus the modulation of cardiac contractility.
- a non- excitatory electrical field current or voltage is passed through the tissue or in its proximity, resulting in either changing trans-membranal calcium ion fluxes or an intracellular calcium stores content.
- the electrical field may interfere/enhance the affinity of intracellular calcium binding elements to calcium.
- the rise in intracellular calcium concentrations may initiate a cascade of events including, but not limited to, phosphorylation/dephosphorylation, gene transcription, and/or post translation modification.
- Systems which utilize the application of electrical current to a tissue, effecting tissue contractility by means of modulating intracellular calcium. At least one pair of electrodes is used for applying the signal. Electrode placement is adapted for achieving the maximum desired effect.
- the electrodes are attached to an either implantable or external device with programming capabilities. This device can be tested and calibrated non-invasively by external mechanisms. In addition, stimulation parameters can be adjusted by a similar programming mechanism.
- the characteristics of the electrodes used for the stimulation are important. This invention utilizes both uni-polar and bi-polar electrode configurations.
- a novel aspect of this method of modulating intracellular calcium in cells is the ability to adjust the timing and the amount of calcium increase/decrease using temporal electrical current rather than systemic pharmacological agents.
- the calcium concentration changes were measured using the florescence ration of a calcium sensitive dye Fura-2 at two wavelengths, 340 nm and 380 nm.
- the same result showing a large increase in calcium concentration was measured from an isolated ferret heart using a Langendorf setting.
- the ventricle contraction force and contractility increased by up to 50%, and at the same time cellular calcium concentration, measured using Aquarine calcium sensitive dye, was increased by up to 50%.
- Figures 2 A and 2B show the effect of the IDS signal on the shortening and intracellular calcium of myocytes isolated from canine heart with heart failure (generated by repeated ischemia events). Each line represents an average of 20 consecutive beats before (black line) and during (gray line) the application of the signal.
- Figure 3 depicts initial changes in contraction force and in action potential duration, measured using an intracellular electrode, during the first three beats of IDS signal application to a rabbit papillary muscle.
- the action potential duration when the IDS signal is applied (gray line in the lower trace) is superimposed on a control contraction (black line in the middle trace). Black lines, in the upper trace, mark the start of application of the IDS signal.
- the action potential duration immediately changes upon the application of the IDS signal from the first pulse. There is no significant difference between action potential duration in the consecutive beats.
- the contraction force behaves differently; there is a small increase in the contraction force on the first beat followed by a larger increase in the second beat and gradual changes until a plateau is reached after 5 to 6 beats.
- the underlying mechanism is that the IDS signal prolongs action potential duration.
- action potential prolongation the flow of calcium into the cell increases and generates two effects: (1) immediate increase in the Sarcolemal calcium level causing the initial increase in the contraction force on the first beat; and
- the initial increase in the contractile force also supports the possible increase in the affinity of intracellular calcium binding elements that cause part of the increase in the contraction force.
- Figure 4 provides additional evidence supporting the hypothesis of calcium entry.
- the lower trace shows the increase in contraction force of a rabbit papillary muscle as a result of an IDS signal (shown as a black line on the upper trace).
- the initial increase in contraction on the first beat followed by the gradual change in the following beats is clearly seen.
- the middle trace shows the change in contraction force of the same muscle after the addition of the Ryanodine to the bath solution.
- Ryanodine prevents the accumulation of calcium in the Sarcoplasmatic Reticulum and therefore decreases the baseline contraction force.
- the contraction force increases immediately on the first beat, but no increase occurs during the following beats since the SR mechanism is disabled by the Ryanodine and no accumulation of calcium in the SR can contribute to the additional increase in contraction force exist.
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU78117/00A AU7811700A (en) | 1999-10-04 | 2000-10-04 | Modulation of intracellular calcium concentration using non-excitatory electrical signals applied to the tissue |
US10/116,201 US8825152B2 (en) | 1996-01-08 | 2002-04-03 | Modulation of intracellular calcium concentration using non-excitatory electrical signals applied to the tissue |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15751199P | 1999-10-04 | 1999-10-04 | |
US60/157,511 | 1999-10-04 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/039,845 Continuation-In-Part US9289618B1 (en) | 1996-01-08 | 2001-10-23 | Electrical muscle controller |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/116,201 Continuation US8825152B2 (en) | 1996-01-08 | 2002-04-03 | Modulation of intracellular calcium concentration using non-excitatory electrical signals applied to the tissue |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001024871A2 true WO2001024871A2 (en) | 2001-04-12 |
WO2001024871A3 WO2001024871A3 (en) | 2002-01-10 |
Family
ID=22564055
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2000/001523 WO2001024871A2 (en) | 1996-01-08 | 2000-10-04 | Modulation of intracellular calcium concentration using non-excitatory electrical signals applied to the tissue |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU7811700A (en) |
WO (1) | WO2001024871A2 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006119467A2 (en) | 2005-05-04 | 2006-11-09 | Impulse Dynamics Nv | Protein activity modification |
WO2007091244A1 (en) | 2006-02-07 | 2007-08-16 | Impulse Dynamics Nv | Assessing cardiac activity |
US8958872B2 (en) | 1996-01-08 | 2015-02-17 | Impulse Dynamics, N.V. | Electrical muscle controller |
US9713723B2 (en) | 1996-01-11 | 2017-07-25 | Impulse Dynamics Nv | Signal delivery through the right ventricular septum |
US9931503B2 (en) | 2003-03-10 | 2018-04-03 | Impulse Dynamics Nv | Protein activity modification |
US11439815B2 (en) | 2003-03-10 | 2022-09-13 | Impulse Dynamics Nv | Protein activity modification |
US11779768B2 (en) | 2004-03-10 | 2023-10-10 | Impulse Dynamics Nv | Protein activity modification |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9289618B1 (en) | 1996-01-08 | 2016-03-22 | Impulse Dynamics Nv | Electrical muscle controller |
US9101765B2 (en) | 1999-03-05 | 2015-08-11 | Metacure Limited | Non-immediate effects of therapy |
US8934975B2 (en) | 2010-02-01 | 2015-01-13 | Metacure Limited | Gastrointestinal electrical therapy |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5320643A (en) * | 1992-10-06 | 1994-06-14 | Medtronic, Inc. | Automatic cardiac capture restoration and threshold-seeking method and apparatus |
US5320642A (en) * | 1990-06-01 | 1994-06-14 | Board Of Regents For The University Of Ok | Method for alleviating and diagnosing symptoms of heart block |
US5871506A (en) * | 1996-08-19 | 1999-02-16 | Mower; Morton M. | Augmentation of electrical conduction and contractility by biphasic cardiac pacing |
US6136019A (en) * | 1996-08-19 | 2000-10-24 | Mower Family Chf Treatment Irrevocable Trust | Augmentation of electrical conduction and contractility by biphasic cardiac pacing administered via the cardiac blood pool |
US6141587A (en) * | 1996-08-19 | 2000-10-31 | Mower Family Chf Treatment Irrevocable Trust | Augmentation of muscle contractility by biphasic stimulation |
-
2000
- 2000-10-04 AU AU78117/00A patent/AU7811700A/en not_active Abandoned
- 2000-10-04 WO PCT/IB2000/001523 patent/WO2001024871A2/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5320642A (en) * | 1990-06-01 | 1994-06-14 | Board Of Regents For The University Of Ok | Method for alleviating and diagnosing symptoms of heart block |
US5320643A (en) * | 1992-10-06 | 1994-06-14 | Medtronic, Inc. | Automatic cardiac capture restoration and threshold-seeking method and apparatus |
US5871506A (en) * | 1996-08-19 | 1999-02-16 | Mower; Morton M. | Augmentation of electrical conduction and contractility by biphasic cardiac pacing |
US6136019A (en) * | 1996-08-19 | 2000-10-24 | Mower Family Chf Treatment Irrevocable Trust | Augmentation of electrical conduction and contractility by biphasic cardiac pacing administered via the cardiac blood pool |
US6141587A (en) * | 1996-08-19 | 2000-10-31 | Mower Family Chf Treatment Irrevocable Trust | Augmentation of muscle contractility by biphasic stimulation |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8958872B2 (en) | 1996-01-08 | 2015-02-17 | Impulse Dynamics, N.V. | Electrical muscle controller |
US9713723B2 (en) | 1996-01-11 | 2017-07-25 | Impulse Dynamics Nv | Signal delivery through the right ventricular septum |
US9931503B2 (en) | 2003-03-10 | 2018-04-03 | Impulse Dynamics Nv | Protein activity modification |
US11439815B2 (en) | 2003-03-10 | 2022-09-13 | Impulse Dynamics Nv | Protein activity modification |
US8977353B2 (en) | 2004-03-10 | 2015-03-10 | Impulse Dynamics Nv | Protein activity modification |
US10352948B2 (en) | 2004-03-10 | 2019-07-16 | Impulse Dynamics Nv | Protein activity modification |
US11779768B2 (en) | 2004-03-10 | 2023-10-10 | Impulse Dynamics Nv | Protein activity modification |
WO2006119467A2 (en) | 2005-05-04 | 2006-11-09 | Impulse Dynamics Nv | Protein activity modification |
WO2007091244A1 (en) | 2006-02-07 | 2007-08-16 | Impulse Dynamics Nv | Assessing cardiac activity |
Also Published As
Publication number | Publication date |
---|---|
WO2001024871A3 (en) | 2002-01-10 |
AU7811700A (en) | 2001-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8825152B2 (en) | Modulation of intracellular calcium concentration using non-excitatory electrical signals applied to the tissue | |
US6298268B1 (en) | Cardiac output controller | |
US6285906B1 (en) | Muscle contraction assist device | |
EP1011795B1 (en) | Cardiac output controller | |
US6442424B1 (en) | Local cardiac motion control using applied electrical signals | |
US8321013B2 (en) | Electrical muscle controller and pacing with hemodynamic enhancement | |
US5690681A (en) | Method and apparatus using vagal stimulation for control of ventricular rate during atrial fibrillation | |
EP1284781B1 (en) | Signal delivery through the right ventricular septum | |
US9713723B2 (en) | Signal delivery through the right ventricular septum | |
US8560067B2 (en) | Apparatus for spatially and temporally distributing cardiac electrical stimulation | |
US7289850B2 (en) | System for enhanced cardiac function with combined PESP/NES | |
EP0530354A1 (en) | Implantable electrical nerve stimulator/pacemaker | |
CA2541386A1 (en) | Cardiac pacing modality having improved blanking, timing, and therapy delivery methods for extra-systolic stimulation pacing therapy | |
EP2032206A1 (en) | System and method for controlling a heart stimulator | |
US7738953B2 (en) | Method and device for preventing plaque formation in coronary arteries | |
US8046064B2 (en) | Method of delivering PESP/ICC as well as adjusting the refractory period of the heart | |
WO2001024871A2 (en) | Modulation of intracellular calcium concentration using non-excitatory electrical signals applied to the tissue | |
US5195518A (en) | System and method for enhancing collateral cardiac blood flow |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10116201 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase in: |
Ref country code: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 10116201 Country of ref document: US |